DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

In Phase C, participants will get ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually condition progression or maybe the participants are not able to tolerate the study drugs.- "Our study uncovered the vital position on the KLF16/MYC regulatory axis in modulatin